RZLT · XBRL financial data

Rezolute financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RZLT's year ends in late June)

In thousands of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Research and development	12,214	12,039	12,401	19,089*	12,754	12,627	15,283	20,863*	13,149	14,348	11,412	14,889*
General and administrative	3,700	3,155	3,812	4,013*	4,187	4,453	4,740	4,987*	6,668	9,873	5,954	6,673*
Total operating expenses	15,914	15,194	16,213	23,102*	16,941	17,080	20,023	25,850*	19,817	24,221	17,366	21,562*
Operating income (loss)	(15,914)	(15,194)	(16,213)	(23,102)*	(16,941)	(17,080)	(20,023)	(25,850)*	(19,817)	(24,221)	(17,366)	(21,562)*
Income tax expense (benefit)	—	—	—	year only	—	—	—	year only	—	—	—	year only
Net income (loss)	(14,524)	(13,909)	(17,050)	(22,976)*	(15,378)	(15,730)	(18,914)	(24,390)*	(18,150)	(22,774)	(16,171)	(20,491)*
Earnings per share, basic USD per share	(0.28)	(0.27)	(0.34)	(0.44)*	(0.22)	(0.22)	(0.27)	(0.26)*	(0.18)	(0.22)	(0.16)	(0.20)*
Earnings per share, diluted USD per share	(0.28)	(0.27)	(0.34)	(0.44)*	(0.22)	(0.22)	(0.27)	(0.26)*	(0.18)	(0.22)	(0.16)	(0.20)*
Weighted average shares, basic thousands of shares	51,409	51,408	50,811	52,233*	69,736	69,940	70,031	94,360*	103,423	103,687	104,040	104,488*
Weighted average shares, diluted thousands of shares	51,409	51,408	50,811	52,233*	69,736	69,940	70,031	94,360*	103,423	103,687	104,040	104,488*

Balance sheet

CSV

Fiscal quarters (RZLT's year ends in late June)

In thousands of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Cash and cash equivalents	8,057	12,504	5,930	70,396	10,472	8,932	14,596	94,107	9,098	11,944	11,236	10,615
Marketable securities	90,673	80,094	74,092	56,478	97,801	87,608	72,296	73,751	143,096	120,994	109,032	97,186
Marketable securities, non-current	8,144	3,352	1,573	263	9,552	8,775	1,514	—	0	0	0	—
Prepaid and other current assets	3,915	3,487	2,188	1,779	1,905	2,154	1,843	3,287	2,514	2,168	1,781	2,710
Total current assets	102,645	96,085	82,210	128,653	110,178	98,694	88,735	171,145	154,708	135,106	122,049	110,511
Property and equipment, net	129	119	110	103	95	87	80	72	64	57	49	41
Right-of-use asset	1,933	2,130	2,006	1,880	1,751	1,619	1,485	1,348	1,208	1,064	918	769
Total assets	112,999	102,150	87,737	132,737	123,414	112,007	94,739	175,490	158,664	138,629	125,459	112,849
Accounts payable	2,432	3,593	3,499	4,901	2,176	3,149	6,502	5,809	3,259	3,783	3,195	5,026
Total current liabilities	7,195	8,008	6,957	9,606	7,991	10,608	10,527	11,912	10,209	9,529	7,704	11,418
Lease liability, non-current	1,814	1,975	1,819	1,660	1,499	1,333	1,160	983	804	619	438	276
Total liabilities	9,435	10,422	16,876	11,734	9,973	12,418	12,170	13,363	11,496	10,631	8,625	12,162
Accumulated deficit	(275,509)	(289,418)	(306,468)	(329,444)	(344,822)	(360,552)	(379,466)	(403,856)	(422,006)	(444,780)	(460,951)	(481,442)
Total stockholders' equity	103,564	91,728	70,861	121,003	113,441	99,589	82,569	162,127	147,168	127,998	116,834	100,687
Total liabilities and equity	112,999	102,150	87,737	132,737	123,414	112,007	94,739	175,490	158,664	138,629	125,459	112,849
Common shares outstanding (cover page) thousands of shares	39,625	39,625	40,135	55,370	57,943	60,535	85,519	90,811	92,728	95,698	96,292	96,722

Cash flows

CSV

Fiscal quarters (RZLT's year ends in late June)

In thousands of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Net income (loss)	(14,524)	(13,909)	(17,050)	(22,976)*	(15,378)	(15,730)	(18,914)	(24,390)*	(18,150)	(22,774)	(16,171)	(20,491)*
Stock-based compensation	1,849	1,837*	1,903*	1,771*	1,400	1,445*	1,905*	2,371*	2,531	3,411*	4,420*	4,098*
Net cash from operating activities	(10,585)	(13,020)*	(15,241)*	(18,522)*	(16,014)	(13,666)*	(17,400)*	(21,995)*	(17,430)	(20,324)*	(13,735)*	(13,146)*
Net cash from investing activities	2,606	17,760*	8,670*	19,663*	(49,410)	11,469*	23,054*	346*	(68,490)	22,814*	12,280*	12,298*
Share repurchases	—	—	—	0*	—	—	—	—	—	—	—	—
Net cash from financing activities	—	—	(3)*	63,325*	5,500	657*	10*	101,160*	911	356*	747*	227*
Net change in cash	(7,979)	4,447*	(6,574)*	64,466*	(59,924)	(1,540)*	5,664*	79,511*	(85,009)	2,846*	(708)*	(621)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Rezolute	10,615	not reported	(13,146)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72,054	0	1,518*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Tvardi Therapeutics	15,765	not reported	(9,228)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156,158	80,104	(27,722)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026
Natures Sunshine Products	82,503	116,985	835*	17.6M	—	Q2 FY26 10-QJun 30, 2026
Palvella Therapeutics	187,803	not reported	(12,845)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.